Optipharm.CO.LTD - Asset Resilience Ratio

Latest as of December 2025: 18.64%

Optipharm.CO.LTD (153710) has an Asset Resilience Ratio of 18.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Optipharm.CO.LTD strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩7.60 Billion

≈ $5.15 Million USD Cash + Short-term Investments

Total Assets

₩40.77 Billion

≈ $27.63 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Optipharm.CO.LTD's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Optipharm.CO.LTD to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Optipharm.CO.LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 153710 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩7.60 Billion	18.64%
Total Liquid Assets	₩7.60 Billion	18.64%

Asset Resilience Insights

Good Liquidity Position: Optipharm.CO.LTD maintains a healthy 18.64% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Optipharm.CO.LTD Industry Peers by Asset Resilience Ratio

Compare Optipharm.CO.LTD's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fleury S.A. SA:FLRY3	Diagnostics & Research	16.06%
Wuhan Thalys Med Tech Co Ltd SHG:603716	Diagnostics & Research	0.12%
Spectral Med Inc TO:EDT	Diagnostics & Research	11.67%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Genetic Signatures Ltd AU:GSS	Diagnostics & Research	60.91%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Optipharm.CO.LTD (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Optipharm.CO.LTD.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	18.64%	₩7.60 Billion ≈ $5.15 Million	₩40.77 Billion ≈ $27.63 Million	-29.86pp
2024-12-31	48.50%	₩21.01 Billion ≈ $14.24 Million	₩43.32 Billion ≈ $29.36 Million	-21.26pp
2023-12-31	69.76%	₩27.40 Billion ≈ $18.57 Million	₩39.28 Billion ≈ $26.62 Million	+5.25pp
2022-12-31	64.51%	₩26.57 Billion ≈ $18.00 Million	₩41.18 Billion ≈ $27.91 Million	-19.11pp
2021-12-31	83.63%	₩34.43 Billion ≈ $23.33 Million	₩41.17 Billion ≈ $27.90 Million	+14.99pp
2020-12-31	68.64%	₩28.36 Billion ≈ $19.22 Million	₩41.32 Billion ≈ $28.00 Million	-4.39pp
2019-12-31	73.03%	₩30.47 Billion ≈ $20.65 Million	₩41.72 Billion ≈ $28.27 Million	+12.24pp
2018-12-31	60.79%	₩25.92 Billion ≈ $17.57 Million	₩42.64 Billion ≈ $28.90 Million	+44.14pp
2017-12-31	16.65%	₩3.30 Billion ≈ $2.24 Million	₩19.84 Billion ≈ $13.45 Million	-2.89pp
2016-12-31	19.54%	₩4.02 Billion ≈ $2.72 Million	₩20.58 Billion ≈ $13.94 Million	--

pp = percentage points

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$46.58 Million

₩68.73 Billion KRW

Market Cap Rank

#22235 Global

#1380 in Korea

Share Price

₩4685.00

Change (1 day)

-2.40%

52-Week Range

₩4400.00 - ₩6200.00

All Time High

₩28900.00